French drugmaker Sanofi is collaborating with Happify Health to advance the use of digital therapeutics in addressing certain mental conditions in patients with multiple sclerosis.
Happify Health, a New York-based technology company that focuses on mental health issues, will develop a version of its digital platform specifically for patients with multiple sclerosis who also experience depression and anxiety.
Sanofi and Happify will jointly develop the digital therapy, which will be submitted to the U.S. Food and Drug Administration for clearance as a medical device.
Following the FDA filing, the companies will evaluate the safety and effectiveness of the therapy for individuals with multiple sclerosis. Happify said it already assessed the effectiveness of an existing, nonspecific solution in reducing anxiety and depression in a general population in 2018.
MTS Health Partners LP served as a financial adviser to Happify Health on the transaction.

